- Conditions
- Healthy Subjects
- Interventions
- 13 valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 15 Months to 18 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 36
- States / cities
- Benton, Arkansas • Fayetteville, Arkansas • Jonesboro, Arkansas + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 260
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pneumococcal Infections
- Interventions
- 13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 2,141 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2011
- U.S. locations
- 26
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 19 more
- Conditions
- Pneumococcal Infections
- Interventions
- V114, Prevnar 13™, PNEUMOVAX™23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 652 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 15
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Spring Valley, California + 12 more
- Conditions
- Inflammatory Response
- Interventions
- Pneumovax 23, Typhim VI, Saline
- Drug · Other
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 249 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
- Interventions
- Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 249 Days to 305 Days
- Enrollment
- 1,128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 39
- States / cities
- Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more
- Conditions
- Healthy
- Interventions
- V118E, PREVNAR 20™, Saline
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Hallandale, Florida • South Miami, Florida • Springfield, Missouri + 1 more
- Conditions
- Streptococcus Pneumoniae
- Interventions
- Placebo, GEN-004 Low Dose, GEN-004 Low Dose + Adjuvant, GEN-004 Mid Dose, GEN-004 Mid Dose + Adjuvant, GEN-004 High Dose, GEN-004 High Dose + Adjuvant
- Biological
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Pneumococcal Infection
- Interventions
- PNEUMOVAX, Prevnar
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 25 Years to 89 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Decatur, Georgia
- Conditions
- Pneumococcal Disease
- Interventions
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 42 Days to 98 Days
- Enrollment
- 1,997 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 105
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 78 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV (GSK3389245A) lower dose formulation vaccine, RSV (GSK3389245A) higher dose formulation vaccine, GSK's multicomponent meningococcal B vaccine, Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine, GSK's pneumococcal polysaccharide conjugate vaccine, GSK's meningococcal group A, C, W-135 and Y conjugate vaccine, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Months to 7 Months
- Enrollment
- 201 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Nampa, Idaho • Louisville, Kentucky + 1 more
- Conditions
- Pneumococcal Infections
- Interventions
- PCV21, 20vPCV
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 7 Months to 17 Years
- Enrollment
- 1,268 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 17
- States / cities
- Paramount, California • Doral, Florida • Hialeah, Florida + 13 more
- Conditions
- Breast Carcinoma, Colorectal Adenocarcinoma, Bladder Carcinoma
- Interventions
- Recombinant human IL-7-hyFc (NT-I7), Vaccine sequence 1, Vaccine sequence 2
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 60 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pneumococcal Conjugate Vaccine
- Interventions
- 13-valent Pneumococcal Conjugate Vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 8 Years to 16 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 2
- States / cities
- Hayward, California • San Jose, California
- Conditions
- Pneumococcal Infection
- Interventions
- V116, PCV20
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,663 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 52 more
- Conditions
- Childhood Cancer, Multiple Diseases
- Interventions
- Immunization Schedule patients <7 years., Immunization Schedule patients > or = to 7 years and <11 years of age, Immunization Schedule patients > or = to 11 years of age
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chickenpox
- Interventions
- Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Huntington Park, California + 18 more
- Conditions
- Pneumococcal Disease
- Interventions
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 42 Days to 98 Days
- Enrollment
- 2,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 23
- States / cities
- Estero, Florida • Fort Lauderdale, Florida • Fort Myers, Florida + 16 more
- Conditions
- Meningitis, Meningococcal Infection
- Interventions
- MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus
- Biological
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 55 Days to 89 Days
- Enrollment
- 7,744 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more
- Conditions
- HIV Infections
- Interventions
- Pneumococcal 7-valent conjugate vaccine, Pneumococcal polysaccharide vaccine, Hepatitis B vaccine, Measles, mumps, and rubella virus vaccine, live
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Years to 23 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Alhambra, California • Long Beach, California + 17 more
- Conditions
- Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease
- Interventions
- ASP3772, PCV13, PPSV23
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 630 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 26
- States / cities
- Banning, California • San Diego, California • San Marcos, California + 21 more
- Conditions
- Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
- Interventions
- Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 1,742 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 69 more
- Conditions
- Herpes Zoster, Pneumococcal Infections
- Interventions
- Enhanced immunization delivery model, Immunization update
- Behavioral · Other
- Lead sponsor
- Auburn University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Auburn, Alabama • Claremont, California
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Belimumab plus Early Vaccination, Belimumab plus Late Vaccination
- Biological
- Lead sponsor
- Human Genome Sciences Inc., a GSK Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Shreveport, Louisiana + 11 more
- Conditions
- Healthy Volunteers (Meningococcal Infection)
- Interventions
- MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine, Pneumococcal 13-valent conjugate vaccine, Pentavalent rotavirus vaccine, Hepatitis B vaccine, Measles, mumps, rubella (MMR) vaccine, Varicella vaccine, Hepatitis A vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 2,627 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more